Gene Sequencer Says Ex-Partner's $138M Deal Broke Promises

Law360, New York (October 26, 2012, 6:56 PM EDT) -- California life sciences outfit Azco Biotech Inc. on Thursday sued Intelligent Bio-Systems Inc., its former partner in a gene-sequencing chemicals and equipment venture, saying IBS' CEO “sold out” Azco for a $138 million merger deal with Dutch DNA technology conglomerate Qiagen NV.

Lured by the fat Qiagen buyout package, Azco and its CEO J. Adams claim, IBS chief Steven J. Gordon was persuaded to abandon an agreement with Azco to mutually develop and sell IBS' MAX-Seq brand genome sequencing equipment and associated reagents. Massachusetts-based IBS left...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Azco Biotech, Inc. et al v. Qiagen, N.V. et al


Case Number

3:12-cv-02599

Court

California Southern

Nature of Suit

Contract: Other

Judge

Roger T. Benitez

Date Filed

October 24, 2012

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.